首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
外语
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu
admin
2013-11-29
97
问题
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolution is based on the idea that the sicker people are, the more freedom they should have to try drugs that are not yet fully tested. For fifty years government policy has been driven by another idea: the fear that insufficiently tested medicines could cause deaths and injuries. The urgent needs of people infected with HIV, the AIDS virus, and the possibility of meeting them with new drugs have created a compelling countervailing force to the continuing concern with safety. As a result, government rules and practices have begun to change. Each step is controversial. But the shift has already gone far beyond AIDS. New ways are emerging for very sick people to try some experimental drugs before they are marketed. People with the most serious forms of heart disease, cancer, emphysema, Alzheimer’ s or Parkinson’ s disease, multiple sclerosis, epilepsy, diabetes, or other grave illnesses can request such drugs through their doctors and are likelier to get them than they would have been four years ago. "We’ve been too rigid in not making lifesaving drugs available to people who otherwise face certain death," says Representative Henry Waxman, of California, who heads the subcommittee that considers changes in drug-approval policies. "It’s true of AIDS, but it’s also true of cancer and other life- threatening diseases."
For the first time, desperate patients have become a potent political force for making new medicines available quickly. People with AIDS and their advocates, younger and angrier than most heart-disease or cancer patients, are drawing on two decades of gay activists’ success in organizing to get what they want from politicians. At times they found themselves allied with Reagan Administration deregulators, scientists, industry representatives, FDA staff members, and sympathetic members of Congress. They organized their own clinical trials and searched out promising drugs here and abroad. The result is a familiar Washington story: a crisis—AIDS—helped crystallize an informal coalition for reform.
AIDS gave new power to old complaints. As early as the 1970s the drug industry and some independent authorities worried that the Food and Do, g Administration’ s testing requirements were so demanding that new drugs were being unreasonably delayed. Beginning in 1972, several studies indicated that the United States had lost its lead in marketing new medicines and that breakthrough drugs—those that show new promise in treating serious or life-threatening diseases— had come to be available much sooner in other countries. Two high-level commissions urged the early release of breakthrough drugs. So did the Carter Administration, but the legislation it pro- posed died in Congress. Complaints were compounded by growing concern that "if we didn’t streamline policies, red tape wot, Id be an obstacle to the development of the biotechnology revolution," as Frank E. Young, who was the head of the FDA from 1984 to 1989, put it in an interview with me.
Young was a key figure in the overhaul of the FDA’s policies. A pioneer in biotechnology and a former dean of the University of Rochester’s medical school, he came to Washington with an agenda and headed the agency for five and a half years—longer than anyone else has since the 1960s. Young took the FDA job to help introduce new medicines created by biotechnology-- whose promise he had seen in his own gene-cloning lab--and to get experimental medicines to desperately iii people more quickly. He had seen people die waiting for new medicines because "they were in the wrong place at the wrong time," he said. That is now changing.
According to the passage, patients who are gravely ill ______.
选项
A、can get experimental drugs more quickly than ever before
B、are still unable to get experimental drugs because of government strict policies
C、can’t afford some expensive experimental drugs
D、refuse to be treated with experimental drugs
答案
A
解析
转载请注明原文地址:https://www.kaotiyun.com/show/qHhO777K
0
考博英语
相关试题推荐
ThedomesticeconomyintheUnitedStatesexpandedinaremarkablyvigorousandsteadyfashion.Therevivalinconsumerconfiden
ThedomesticeconomyintheUnitedStatesexpandedinaremarkablyvigorousandsteadyfashion.Therevivalinconsumerconfiden
Themarveloustelephoneandtelevisionnetworkthathasnowenmeshedthewholeworld,makingallmenneighbors,cannotbeextend
Justiceinsocietymustincludebothafairtrialtotheaccusedandtheselectionofanappropriatepunishmentforthoseproven
Variousinnovationshavebeenintroducedaswaystobreakoffoursystemwhichforcesstudentsthroughaseriesofidenticalcla
Whenitcomestotheslowingeconomy,EllenSpiroisn’tbitinghernailsjustyet.Butthe47-year-oldmanicuristisn’tcutting,
TheInternetisaglobalnetworkthatconnectsothercomputernetworks,togetherwithsoftwareandprotocolsforcontrollingthe
Anestheticsaresubstances____todeadenpainorproduceaconditioninwhichsomeorallofthesenses,especiallytouch,stopfun
随机试题
设备设计监理的主要工作内容不包括下面的()。
上尿路结石最常见的类型是
《环境影响评价公众参与暂行办法》规定:国家鼓励公众参与环境影响评价活动。公众参与实行()的原则。
建设工程的协调不包括( )。
设n为正整数,且n<<n+1,则n的值为______。
影响人身心发展的内部因素是()。
1,3,0,6,10,9,()。
冻疮是冬季常见病,在气温低、空气潮湿的环境容易发生,多发生在肢体的末梢和暴露的部位,它是由于皮肤的()受损而引起的。
已知,某公司2015年12月31日的长期负债及所有者权益总额为18000万元,其中,发行在外的普通股8000万股(每股面值1元),公司债券2000万元,按面值发行,票面年利率为8%,每年年末付息,3年后到期。资本公积4000万元,其余均为留存收益。
难于运用是()的主要缺陷o
最新回复
(
0
)